MARTINSRIED, Germany, Feb. 28, 2006 (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard:MOR) today announced the achievement of a fourth therapeutic milestone within the scope of its collaboration with Centocor Inc. In meeting the milestone, MorphoSys developed several highly optimized fully human IgG antibodies using its proprietary HuCAL GOLD(r) antibody library against a Centocor target involved in inflammatory and auto-immune diseases. As part of the collaboration milestone, MorphoSys applied its proprietary HuCAL GOLD(r) antibody library in order to generate antibodies which passed pre-defined criteria. Achievement of the milestone triggered a payment from Centocor to MorphoSys. Further financial details were not disclosed.
